What is Zacks Research’s Forecast for McKesson Q2 Earnings?

McKesson Co. (NYSE:MCK) – Zacks Research decreased their Q2 2026 earnings estimates for shares of McKesson in a report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now expects that the company will post earnings per share of $8.39 for the quarter, down from their previous estimate of $8.51. The consensus estimate for McKesson’s current full-year earnings is $31.91 per share. Zacks Research also issued estimates for McKesson’s FY2026 earnings at $35.05 EPS, Q1 2027 earnings at $8.03 EPS, Q2 2027 earnings at $9.04 EPS and FY2027 earnings at $40.21 EPS.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, beating the consensus estimate of $7.21 by $0.67. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The firm had revenue of $79.28 billion for the quarter, compared to analysts’ expectations of $82.53 billion. During the same quarter last year, the company earned $7.27 EPS. McKesson’s quarterly revenue was up 6.4% on a year-over-year basis.

MCK has been the subject of several other research reports. Baird R W lowered shares of McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Wells Fargo & Company reduced their price objective on shares of McKesson from $576.00 to $535.00 and set an “equal weight” rating for the company in a research report on Friday, September 13th. Citigroup reduced their price objective on shares of McKesson from $670.00 to $630.00 and set a “buy” rating for the company in a research report on Tuesday, September 10th. Leerink Partners reduced their price objective on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Finally, StockNews.com cut shares of McKesson from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $610.86.

McKesson Trading Up 0.5 %

NYSE:MCK opened at $507.41 on Friday. McKesson has a twelve month low of $431.35 and a twelve month high of $637.51. The company has a 50-day moving average of $516.67 and a 200-day moving average of $550.88. The firm has a market cap of $65.80 billion, a price-to-earnings ratio of 22.69, a price-to-earnings-growth ratio of 1.18 and a beta of 0.44.

Institutional Trading of McKesson

Several institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in shares of McKesson by 1.1% during the first quarter. JPMorgan Chase & Co. now owns 4,362,837 shares of the company’s stock worth $2,342,190,000 after purchasing an additional 46,659 shares during the period. Legal & General Group Plc raised its position in McKesson by 2.9% during the second quarter. Legal & General Group Plc now owns 1,297,620 shares of the company’s stock valued at $757,862,000 after acquiring an additional 36,583 shares in the last quarter. Swedbank AB bought a new position in McKesson during the first quarter valued at approximately $669,326,000. Boston Partners raised its position in McKesson by 4.1% during the first quarter. Boston Partners now owns 1,183,829 shares of the company’s stock valued at $635,763,000 after acquiring an additional 47,140 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in McKesson by 7.9% during the second quarter. AQR Capital Management LLC now owns 857,611 shares of the company’s stock valued at $500,879,000 after acquiring an additional 62,875 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $561.10, for a total transaction of $2,105,808.30. Following the completion of the sale, the chief executive officer now directly owns 78,586 shares in the company, valued at approximately $44,094,604.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.11% of the stock is currently owned by corporate insiders.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, October 1st. Investors of record on Monday, September 2nd were issued a dividend of $0.71 per share. This is a boost from McKesson’s previous quarterly dividend of $0.62. This represents a $2.84 annualized dividend and a dividend yield of 0.56%. The ex-dividend date of this dividend was Friday, August 30th. McKesson’s dividend payout ratio (DPR) is currently 12.70%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.